Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 25 2026

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced that it received approval from the DCGI to initiate Phase III trials for Zintrodiazine, a new anti-malarial candidate. The trials will focus on patients with uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax. This development is seen as a significant step in addressing the growing resistance to current malaria treatments. The press release emphasizes Zydus's commitment to innovation in healthcare and the importance of combating malaria.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 25, 2026, titled "Zydus receives approval from DCGI to initiate Phase III trials of Zintrodiazine, a novel anti-malarial candidate".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases